The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is the first randomized controlled trial that seeks to identify women in which digital breast tomosynthesis (DBT) may outperform (2D) digital mammography in reducing advanced breast cancer development.
The study will create the world’s largest curated dataset of breast cancer screening clinical data, images and bio-specimens to help researchers tailor future screening to a woman’s individual risk.
TMIST is enrolling 165,000 healthy women ages 45 to 74 at 130 sites throughout North America.
ECOG-ACRIN membership requires a site Cancer Therapy Evaluation Program (CTEP) ID number (see Site Needs below), completion of an ECOG-ACRIN membership application, and submission of a CV for the principal investigator.
The study pays facilities $500 for the submission of data on each insured and uninsured subject enrolled through National Clinical Trials Network (NCTN) group affiliation.
TMIST also pays sites $150 for data on each follow-up screening mammogram (digital mammogram or digital breast tomosynthesis) required under the study protocol for patients with private insurance, Medicare or Medicaid. NCI Community Oncology Research Program (NCORP) sites receive equivalent NCORP credits. These payments are in addition to the insurer payment to cover the cost of the exam.
TMIST also pays facilities $288 per study ($138.17 for performing each exam + $150 for data submission for each exam) for uninsured subjects who qualify for charity care at the site. This payment can be applied for each time a screening exam is required in the study for uninsured women.
Additional TMIST payments are received for submission of biopsy samples and blood and buccal smear samples. NCORP sites receive equivalent NCORP credits.
TMIST Radiology-Industry News